Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B-cells.
Merel A A OpdamJ H de LeijerNathan den BroederRogier M ThurlingsWilfred van der WeeleMichael T NurmohamedMarc R KokLenny van BonDavid F Ten CateLise M VerhoefAlfons A den BroederPublished in: Rheumatology (Oxford, England) (2022)
These secondary analyses of the REDO trial confirmed the observed dose-dependent infection risk. Additionally, we found that infection risks were higher shortly after RTX infusion. However, a mediating pathway was not found.